volume 26, issue 6, P311-320 2018
DOI: 10.1007/s12471-018-1118-0
View full text
|
Sign up to set email alerts
|
Share

Abstract: Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism, predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies have been developed. At present, non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy for stroke prevention in patients with non-valvular atrial fibrillation (i.e. without a mechanical valve prosthesis or rheumatic heart disease). Considering th…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

1
2
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals